Health Care & Life Sciences » Biotechnology | Trillium Therapeutics Inc.

Trillium Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
32,983.10
26,165.10
86,770.50
50,473.00
81,791.00
45,409
Total Accounts Receivable
427.20
344.40
974.80
526.50
669.00
1,101
Other Current Assets
94.60
1,008.20
1,181.50
402.70
960.00
1,031
Total Current Assets
33,504.90
27,517.70
88,926.80
51,402.20
83,420.00
47,541
Net Property, Plant & Equipment
109.00
235.40
897.40
3,260.00
2,882.00
2,155
Intangible Assets
1,473.50
432.90
93.60
11,849.60
7,990.00
5,652
Other Assets
-
-
121.70
110.90
111.00
111
Total Assets
35,087.40
28,186.00
90,039.50
66,622.70
94,403.00
55,459
ST Debt & Current Portion LT Debt
62.80
-
-
-
-
Accounts Payable
113.00
1,604.50
-
-
-
Other Current Liabilities
556.90
1,923.90
3,556.90
5,915.60
14,520.00
Total Current Liabilities
732.60
3,528.40
3,556.90
5,915.60
14,520.00
Long-Term Debt
446.30
283.40
270.40
190.60
98.00
Other Liabilities
-
69.90
408.30
2,397.00
1,208.00
Total Liabilities
1,178.90
3,881.70
4,235.60
8,503.20
15,826.00
Common Equity (Total)
22,615.90
14,228.10
53,636.70
26,033.90
25,871.00
Total Shareholders' Equity
33,908.40
24,304.30
85,803.90
58,119.50
78,577.00
Total Equity
33,908.40
24,304.30
85,803.90
58,119.50
78,577.00
Liabilities & Shareholders' Equity
35,087.40
28,186.00
90,039.50
66,622.70
94,403.00
Preferred Stock (Carrying Value)
11,292.50
10,076.20
32,167.20
32,085.60
52,706.00

About Trillium Therapeutics

View Profile
Address
2488 Dunwin Drive
Mississauga Ontario L5L 1J9
Canada
Employees -
Website http://www.trilliumtherapeutics.com
Updated 07/08/2019
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.